Staff Picks /Features

ISAL 2017: Developments in acute leukemias

The International Symposium on Acute Leukemias (ISAL) 2017 was, as always, filled with data, scientific developments and debate. To capture…

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…

Educational /Features

The Evolution of Chemotherapy

Using the A-DAC principle to unlock new treatment options in Hodgkin lymphoma On the 23rd of October, 2016 a panel…

Biosimiliars

Can the dream of affordable cancer care come true?

UNITY clinical trials

TGR-1202 shows promise in CLL and DLBCL TGR-1202 is a novel PI3K inhibitor currently being tested in the clinical setting…

Zydelig®▼ (idelalisib)

Updated advice following conclusion of a safety review     Julian Cole, MA, MRCPI, Dip Pharm Med, FFPM, the UK…

EHA 2016 satellite symposium

Optimizing treatment for patients with CP-CML and Ph+ ALL The 2016 European Hematology Association (EHA) Annual Congress took place during…

Most Recent /Features

ISAL 2017: Developments in acute leukemias

The International Symposium on Acute Leukemias (ISAL) 2017 was, as always, filled with data, scientific developments and debate. To capture…

Innovative Medicines Initiative approves €40 million HARMONY project for better care of patients with hematologic malignancies

The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients…

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma

As usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We…

Positive Phase III results for plitidepsin

Plitidepsin (also known as dehydrodidemnin B) is a first-in-class drug originally obtained from the sea squirt Aplidium albicans.[1] Plitidepsin specifically…